Different doses of canakinumab were evaluated in stable CAD patients with a prior MI and persistent inflammation (high-sensitivity CRP ≥2 mg/L) in the CANTOS trial.25,26 This study is considered a landmark, as it was the first to provide direct evidence supporting the inflammatory hypothesis in atherosclerosis. This evidence concerns the gene CRP and coronary artery disorder.